STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

Call for corporate homicide probe over claims NHS Grampian patients unnecessarily bled to death

Measles has come raging back in the US. Robert F Kennedy Jr should be impeached | Judith Levine

STAT+: Before midterm losses, MAHA spent on itself instead of candidates
